Arcturus Therapeutics ( ARCT ) Reports Q3 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 62.86% and 15.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
| Ticker |
Sentiment |
Impact |
|
ARCT
|
Neutral
|
40 %
|
|
BOLT
|
Neutral
|
21 %
|
